The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s nasal spray, Spravato, as a standalone treatment for adults with major depressive disorder (MDD) that is resistant to conventional therapies. This marks a significant development in the treatment of depression, as Spravato becomes the first FDA-approved standalone therapy for treatment-resistant depression (TRD). The decision reflects the growing acceptance of the drug, which recorded $780 million in sales in the first nine months of 2024.
Spravato, which entered the U.S. market in 2019, was previously approved for use alongside oral antidepressants to treat TRD and acute suicidal ideation in MDD patients. This new approval allows it to be administered without oral antidepressants, providing a vital option for patients whose symptoms do not improve with traditional treatments or who experience adverse effects like weight gain and sexual dysfunction.
The decision is based on data from a phase four clinical trial showing that Spravato alone can improve depressive symptoms as quickly as 24 hours after administration, with effects lasting at least a month. Johnson & Johnson stated that the drug’s safety profile in the standalone trial aligned with prior findings from its combination use with oral antidepressants. Dr. Gregory Mattingly, president of the Midwest Research Group and a participant in Spravato’s clinical trials, emphasized the transformative potential of this treatment.
His St. Louis facility, one of 3,000 certified outpatient centers in the U.S., has treated over 6,000 patients with Spravato, offering hope to those who have struggled with inadequate responses to other medications. Spravato’s active ingredient, esketamine, is derived from ketamine, an anesthetic known for its rapid action in the brain. The nasal spray enables faster symptom relief compared to traditional oral antidepressants, which often take weeks to demonstrate efficacy.
However, its potential risks, including sedation, dissociation, and misuse, necessitate strict monitoring. Patients must be supervised for two hours after administration in certified healthcare settings, as the drug is not available for pharmacy purchase. Johnson & Johnson anticipates Spravato becoming a blockbuster product, projecting annual sales between $1 billion and $5 billion. This growth could offset potential challenges from patent expirations and Medicare price negotiations affecting its top-selling drug, Stelara.
The approval underscores the importance of personalized approaches in mental health treatment. Bill Martin, J&J’s global head of neuroscience, highlighted how this new option enables patients and caregivers to tailor treatment plans effectively. With increased physician familiarity and real-world data supporting its efficacy, Spravato is poised to redefine management strategies for treatment-resistant depression. Spravato’s trajectory reflects growing confidence within the medical community. As mental health care evolves, this FDA approval represents a critical step in addressing the unmet needs of millions living with depression. – By MENA Newswire News Desk.
